Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.75 |
| ▸ | PTGER2 | P43116 | 14/20 | 0.75 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15587037 | 1.00 | PTGER4 (0.75) | PTGER4PTGER2PTGER3 | |
| SCHEMBL16819284 | 1.00 | PTGER4 (0.75) | PTGER4PTGER2PTGER3 | |
| SCHEMBL16819281 | 1.00 | PTGER4 (0.75) | PTGER4PTGER2PTGER3 | |
| SCHEMBL18943959 | 1.00 | PTGER4 (0.75) | PTGER4PTGER2PTGER3 | |
| SCHEMBL19328445 | 0.93 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 | |
| SCHEMBL22025494 | 0.93 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 | |
| SCHEMBL16819195 | 0.93 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 | |
| SCHEMBL16819196 | 0.93 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 | |
| SCHEMBL15586946 | 0.93 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 | |
| SCHEMBL19328450 | 0.92 | PTGER4 (0.77) | PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-10556862-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20170260173-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS | MYOMETRICS, LLC (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556862-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
| US-20170260173-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDTIONS | PTGER4, PTGER1, EPB41 | PTGER4 1/4885PTGER2 5/4885PTGER3 4/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.